Sagely Health
@sagelyhealth.bsky.social
We make cancer easier. Expert, unbiased guidance on treatment, trials & diagnostics. We decode your options, connect you to top doctors, and help you act with confidence. Start: sagelyhealth.com
🩸 ASH 2025 Heme Highlights — Round 1 is live
This first ASH roundup pulls together:
• 73 new blood cancer findings
• 13 SPOTLIGHT studies
• Early signals likely to influence practice
This first ASH roundup pulls together:
• 73 new blood cancer findings
• 13 SPOTLIGHT studies
• Early signals likely to influence practice
2025 ASH Week Heme Highlights (Round 1)
First wave of practice-shaping blood cancer data from ASH 2025—deep remissions, new backbones, and bold salvage options.
open.substack.com
December 17, 2025 at 6:26 PM
🩸 ASH 2025 Heme Highlights — Round 1 is live
This first ASH roundup pulls together:
• 73 new blood cancer findings
• 13 SPOTLIGHT studies
• Early signals likely to influence practice
This first ASH roundup pulls together:
• 73 new blood cancer findings
• 13 SPOTLIGHT studies
• Early signals likely to influence practice
November 14, 2025 at 9:11 PM
When a small breast cancer is found, many people have a lumpectomy. The goal is “clear margins”—no cancer at the edge of what’s removed. If cancer is on the edge, a second surgery is often needed; in some settings it can be about 3 in 10.
November 10, 2025 at 6:49 PM
When a small breast cancer is found, many people have a lumpectomy. The goal is “clear margins”—no cancer at the edge of what’s removed. If cancer is on the edge, a second surgery is often needed; in some settings it can be about 3 in 10.
After CRC surgery, a ctDNA blood test can detect tiny traces of cancer even when scans look clear.
A new clinical trial asks if treating now—because ctDNA is positive—reduces recurrence.
A new clinical trial asks if treating now—because ctDNA is positive—reduces recurrence.
October 29, 2025 at 7:42 PM
After CRC surgery, a ctDNA blood test can detect tiny traces of cancer even when scans look clear.
A new clinical trial asks if treating now—because ctDNA is positive—reduces recurrence.
A new clinical trial asks if treating now—because ctDNA is positive—reduces recurrence.
Some breast cancers have extra EGFR—about 1 in 5 overall, and more often in TNBC. Think of EGFR as a growth antenna.
October 28, 2025 at 5:15 PM
Some breast cancers have extra EGFR—about 1 in 5 overall, and more often in TNBC. Think of EGFR as a growth antenna.
When Trodelvy stops working in TNBC, what’s next?
New idea: bulumtatug furvedotin, an ADC that locks onto the nectin-4 marker and brings a cell-division-blocking chemo payload to the tumor.
(more ->)
New idea: bulumtatug furvedotin, an ADC that locks onto the nectin-4 marker and brings a cell-division-blocking chemo payload to the tumor.
(more ->)
Breast Cancer Briefing | Sagely Health | Substack
Your concise scan of the latest breakthroughs & new trials for breast cancer. Click to read Breast Cancer Briefing, by Sagely Health, a Substack publication. Launched 3 months ago.
breastcancerbriefing.substack.com
October 24, 2025 at 5:21 PM
When Trodelvy stops working in TNBC, what’s next?
New idea: bulumtatug furvedotin, an ADC that locks onto the nectin-4 marker and brings a cell-division-blocking chemo payload to the tumor.
(more ->)
New idea: bulumtatug furvedotin, an ADC that locks onto the nectin-4 marker and brings a cell-division-blocking chemo payload to the tumor.
(more ->)
🎗️ Breast Cancer Awareness Month
If you’re weighing treatment choices, put clinical trials on the table early. Many are designed for specific tumor markers and can be options before, during, or after standard care.
If you’re weighing treatment choices, put clinical trials on the table early. Many are designed for specific tumor markers and can be options before, during, or after standard care.
October 2025: 10 New Breast Cancer Clinical Trials
New trials mean new treatment options. See if anything matches your situation.
breastcancerbriefing.substack.com
October 23, 2025 at 5:30 PM
🎗️ Breast Cancer Awareness Month
If you’re weighing treatment choices, put clinical trials on the table early. Many are designed for specific tumor markers and can be options before, during, or after standard care.
If you’re weighing treatment choices, put clinical trials on the table early. Many are designed for specific tumor markers and can be options before, during, or after standard care.
🎗️ For Breast Cancer Awareness Month
🩸A quick read on ctDNA—a blood test that looks for tiny traces of tumor DNA and may flag changes before scans do.
What it can (and can’t) tell you → breastcancerbriefing.substack.com/p/catching-c...
🩸A quick read on ctDNA—a blood test that looks for tiny traces of tumor DNA and may flag changes before scans do.
What it can (and can’t) tell you → breastcancerbriefing.substack.com/p/catching-c...
Catching Cancer’s Hidden Signals: ctDNA Testing in Breast Cancer
What breast cancer patients need to know about this simple blood test
breastcancerbriefing.substack.com
October 20, 2025 at 9:22 PM
🎗️ For Breast Cancer Awareness Month
🩸A quick read on ctDNA—a blood test that looks for tiny traces of tumor DNA and may flag changes before scans do.
What it can (and can’t) tell you → breastcancerbriefing.substack.com/p/catching-c...
🩸A quick read on ctDNA—a blood test that looks for tiny traces of tumor DNA and may flag changes before scans do.
What it can (and can’t) tell you → breastcancerbriefing.substack.com/p/catching-c...
🎗️ A Breast Cancer Awareness Month reminder
Back in 2022, they approved Enhertu for people with HER2-low breast cancer. This year, they opened it up so even more people with HER2-low can get it—earlier in treatment, not just after chemo.
Here’s the part most folks don’t realize:
Back in 2022, they approved Enhertu for people with HER2-low breast cancer. This year, they opened it up so even more people with HER2-low can get it—earlier in treatment, not just after chemo.
Here’s the part most folks don’t realize:
October 13, 2025 at 10:49 PM
🎗️ A Breast Cancer Awareness Month reminder
Back in 2022, they approved Enhertu for people with HER2-low breast cancer. This year, they opened it up so even more people with HER2-low can get it—earlier in treatment, not just after chemo.
Here’s the part most folks don’t realize:
Back in 2022, they approved Enhertu for people with HER2-low breast cancer. This year, they opened it up so even more people with HER2-low can get it—earlier in treatment, not just after chemo.
Here’s the part most folks don’t realize:
NSCLC isn’t one disease—tumor features like EGFR matter. After surgery, some people already benefit from a pill if they have the common EGFR mutations.
For the uncommon exon 20 insertion...
For the uncommon exon 20 insertion...
New in Oncology - Oct 3, 2025
Three clear standouts (MM, melanoma, pediatric ALK+) — plus 28 new trials worth a look.
sagelyhealth.substack.com
October 3, 2025 at 10:01 PM
NSCLC isn’t one disease—tumor features like EGFR matter. After surgery, some people already benefit from a pill if they have the common EGFR mutations.
For the uncommon exon 20 insertion...
For the uncommon exon 20 insertion...
Radiation usually comes from outside the body. This trial explores guided “inside” radiation for colorectal cancer.
✅ A scan for GRPR (a kind of tumor doorbell).
✅ If GRPR+, the study drug LY4257496 is designed to find that signal and deliver a small dose of radiation right there, sometimes...
✅ A scan for GRPR (a kind of tumor doorbell).
✅ If GRPR+, the study drug LY4257496 is designed to find that signal and deliver a small dose of radiation right there, sometimes...
October 2, 2025 at 3:56 AM
Radiation usually comes from outside the body. This trial explores guided “inside” radiation for colorectal cancer.
✅ A scan for GRPR (a kind of tumor doorbell).
✅ If GRPR+, the study drug LY4257496 is designed to find that signal and deliver a small dose of radiation right there, sometimes...
✅ A scan for GRPR (a kind of tumor doorbell).
✅ If GRPR+, the study drug LY4257496 is designed to find that signal and deliver a small dose of radiation right there, sometimes...
After chemo, what keeps CRC from sneaking back?
A simple guide to smarter maintenance in colorectal cancer.
A simple guide to smarter maintenance in colorectal cancer.
Beyond the Finish Line for CRC
New Advances in Colorectal Cancer Maintenance Care
colorectalcancer.substack.com
September 30, 2025 at 6:28 PM
After chemo, what keeps CRC from sneaking back?
A simple guide to smarter maintenance in colorectal cancer.
A simple guide to smarter maintenance in colorectal cancer.
Simply put by one of our readers: "Your Substack articles are nice and quick to skim through, but also detailed enough to walk away with good knowledge of what's new in the cancer research world."
Oncology Intel (weekly): sagelyhealth.substack.com
#colorectalcancer #BreastCancer #oncology
Oncology Intel (weekly): sagelyhealth.substack.com
#colorectalcancer #BreastCancer #oncology
Oncology Intel by Sagely Health | Substack
Your go-to weekly source of clinical trials news and treatment insights. Click to read Oncology Intel by Sagely Health, a Substack publication with hundreds of subscribers.
sagelyhealth.substack.com
September 29, 2025 at 8:46 PM
Simply put by one of our readers: "Your Substack articles are nice and quick to skim through, but also detailed enough to walk away with good knowledge of what's new in the cancer research world."
Oncology Intel (weekly): sagelyhealth.substack.com
#colorectalcancer #BreastCancer #oncology
Oncology Intel (weekly): sagelyhealth.substack.com
#colorectalcancer #BreastCancer #oncology
Cancer trial search is exhausting.
We built a better way.
Short intake → optional records → we find and prioritize cancer trials by weighing promising efficacy & safety signals (not just eligibility), so the best options surface.
Early access (free): www.sagelyhealth.com/find-a-clini...
#cancer
We built a better way.
Short intake → optional records → we find and prioritize cancer trials by weighing promising efficacy & safety signals (not just eligibility), so the best options surface.
Early access (free): www.sagelyhealth.com/find-a-clini...
#cancer
The smart way to find the right clinical trials for your cancer
Answer a few quick questions, upload records if you have them, and we’ll search tens of thousands of cancer trials to uncover the ones that may fit your situation. Your personalized results arrive dir...
www.sagelyhealth.com
September 25, 2025 at 10:21 PM
Cancer trial search is exhausting.
We built a better way.
Short intake → optional records → we find and prioritize cancer trials by weighing promising efficacy & safety signals (not just eligibility), so the best options surface.
Early access (free): www.sagelyhealth.com/find-a-clini...
#cancer
We built a better way.
Short intake → optional records → we find and prioritize cancer trials by weighing promising efficacy & safety signals (not just eligibility), so the best options surface.
Early access (free): www.sagelyhealth.com/find-a-clini...
#cancer
Clinical trial: EGFR-targeted “smart chemo” (ALX2004) for metastatic colorectal cancer.
The ADC seeks the EGFR “flag” and delivers chemo right to those cells. For EGFR+ mCRC after standard meds have stopped helping.
The ADC seeks the EGFR “flag” and delivers chemo right to those cells. For EGFR+ mCRC after standard meds have stopped helping.
September 23, 2025 at 6:52 PM
Clinical trial: EGFR-targeted “smart chemo” (ALX2004) for metastatic colorectal cancer.
The ADC seeks the EGFR “flag” and delivers chemo right to those cells. For EGFR+ mCRC after standard meds have stopped helping.
The ADC seeks the EGFR “flag” and delivers chemo right to those cells. For EGFR+ mCRC after standard meds have stopped helping.
Keeping up with oncology shouldn’t be a full-time job…but it is.
Since May, our weekly Oncology Intel has distilled the firehose:
18 issues
316 notable findings
633 new trials across nearly every cancer type
Clear summaries, actionable signals, no fluff.
Subscribe free: sagelyhealth.substack.com
Since May, our weekly Oncology Intel has distilled the firehose:
18 issues
316 notable findings
633 new trials across nearly every cancer type
Clear summaries, actionable signals, no fluff.
Subscribe free: sagelyhealth.substack.com
Oncology Intel by Sagely Health | Substack
Your go-to weekly source of clinical trials news and treatment insights. Click to read Oncology Intel by Sagely Health, a Substack publication. Launched 4 months ago.
sagelyhealth.substack.com
September 19, 2025 at 8:53 PM
Keeping up with oncology shouldn’t be a full-time job…but it is.
Since May, our weekly Oncology Intel has distilled the firehose:
18 issues
316 notable findings
633 new trials across nearly every cancer type
Clear summaries, actionable signals, no fluff.
Subscribe free: sagelyhealth.substack.com
Since May, our weekly Oncology Intel has distilled the firehose:
18 issues
316 notable findings
633 new trials across nearly every cancer type
Clear summaries, actionable signals, no fluff.
Subscribe free: sagelyhealth.substack.com
If your metastatic breast cancer has grown after endocrine therapy, chemo, and possibly an ADC, this is a clinical trial to know about.
Many breast cancers display TROP2—a protein “flag” on the tumor surface. A new clinical trial...
Many breast cancers display TROP2—a protein “flag” on the tumor surface. A new clinical trial...
September 16, 2025 at 7:32 PM
If your metastatic breast cancer has grown after endocrine therapy, chemo, and possibly an ADC, this is a clinical trial to know about.
Many breast cancers display TROP2—a protein “flag” on the tumor surface. A new clinical trial...
Many breast cancers display TROP2—a protein “flag” on the tumor surface. A new clinical trial...
Oncology isn’t slowing down.
This week’s brief: 20 new trials, dose clarity for T-DXd in HER2-mutant lung, and an early GVHD-sparing AML CAR-T signal—all in one fast read.
We do this every week so you don’t have to chase everything.
Read & subscribe → sagelyhealth.substack.com/p/new-in-onc...
This week’s brief: 20 new trials, dose clarity for T-DXd in HER2-mutant lung, and an early GVHD-sparing AML CAR-T signal—all in one fast read.
We do this every week so you don’t have to chase everything.
Read & subscribe → sagelyhealth.substack.com/p/new-in-onc...
New in Oncology - Sept 12, 2025
T-DXd dose clarity and a GVHD-sparing AML CAR-T hint lead the week (+20 trials)
sagelyhealth.substack.com
September 12, 2025 at 7:30 PM
Oncology isn’t slowing down.
This week’s brief: 20 new trials, dose clarity for T-DXd in HER2-mutant lung, and an early GVHD-sparing AML CAR-T signal—all in one fast read.
We do this every week so you don’t have to chase everything.
Read & subscribe → sagelyhealth.substack.com/p/new-in-onc...
This week’s brief: 20 new trials, dose clarity for T-DXd in HER2-mutant lung, and an early GVHD-sparing AML CAR-T signal—all in one fast read.
We do this every week so you don’t have to chase everything.
Read & subscribe → sagelyhealth.substack.com/p/new-in-onc...
Doctors are testing a smarter way to aim radiation.
Some breast cancers have lots of GRPR, a protein on the tumor surface (common in ER+ disease).
A radioligand is a tracer carrying a micro-dose of radiation that travels in the blood...
Some breast cancers have lots of GRPR, a protein on the tumor surface (common in ER+ disease).
A radioligand is a tracer carrying a micro-dose of radiation that travels in the blood...
September 11, 2025 at 11:53 PM
Doctors are testing a smarter way to aim radiation.
Some breast cancers have lots of GRPR, a protein on the tumor surface (common in ER+ disease).
A radioligand is a tracer carrying a micro-dose of radiation that travels in the blood...
Some breast cancers have lots of GRPR, a protein on the tumor surface (common in ER+ disease).
A radioligand is a tracer carrying a micro-dose of radiation that travels in the blood...
🌸 September’s Breast Cancer Briefing is here: 18 new trials.
🔹 Screening for dense breasts
🔹 Smarter radiation schedules
🔹 A blood-test–guided drug for TNBC
Trials = options. Free resource for patients & caregivers.
👉 breastcancerbriefing.substack.com/p/september-...
🔹 Screening for dense breasts
🔹 Smarter radiation schedules
🔹 A blood-test–guided drug for TNBC
Trials = options. Free resource for patients & caregivers.
👉 breastcancerbriefing.substack.com/p/september-...
September 2025: 18 New Breast Cancer Clinical Trials
Trials expand your treatment options. Here's the breakdown of the newest trials.
breastcancerbriefing.substack.com
September 10, 2025 at 4:11 PM
🌸 September’s Breast Cancer Briefing is here: 18 new trials.
🔹 Screening for dense breasts
🔹 Smarter radiation schedules
🔹 A blood-test–guided drug for TNBC
Trials = options. Free resource for patients & caregivers.
👉 breastcancerbriefing.substack.com/p/september-...
🔹 Screening for dense breasts
🔹 Smarter radiation schedules
🔹 A blood-test–guided drug for TNBC
Trials = options. Free resource for patients & caregivers.
👉 breastcancerbriefing.substack.com/p/september-...